Sugi Predict

Sugi Predict / Compounds / SCHEMBL253500

SCHEMBL253500

SCHEMBL253500

CN(C)C(=O)Cn1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.57
▸ PDK2 Q15119 1/20 0.42
▸ CCNC P24863 9/20 0.40
▸ CDK8 P49336 9/20 0.40
▸ FLT3 P36888 1/20 0.40
▸ MYLK Q15746 1/20 0.40
▸ AURKB Q96GD4 1/20 0.40
▸ CILK1 Q9UPZ9 1/20 0.40
▸ CDK11A Q9UQ88 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ TYK2 P29597 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ ALOX5AP P20292 3/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ DGAT1 O75907 1/20 0.34
▸ GSK3A P49840 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ RET P07949 1/20 0.34
▸ IRAK1 P51617 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14543046 0.89 FFAR1 (0.45) FFAR1PDK2CCNCCDK8FLT3
SCHEMBL31313005 0.86 FFAR1 (0.54) FFAR1PDK2DGAT1GSK3AGSK3B
SCHEMBL19656319 0.86 CCNC (0.52) FFAR1PDK2CCNCCDK8FLT3
SCHEMBL12912195 0.84 FFAR1 (0.61) FFAR1DGAT1GSK3AGSK3BIRAK4
SCHEMBL2680105 0.84 FFAR1 (0.61) FFAR1PDK2DGAT1GSK3AGSK3B
SCHEMBL2544457 0.83 FFAR1 (0.59) FFAR1PDK2DGAT1GSK3AGSK3B
SCHEMBL14232005 0.82 FFAR1 (0.58) FFAR1PDK2CCNCCDK8JAK3
SCHEMBL12049576 0.82 FFAR1 (0.58) FFAR1DGAT1GSK3AGSK3BUCHL1
SCHEMBL938503 0.81 FFAR1 (0.54) FFAR1JAK2JAK1TYK2JAK3
SCHEMBL4099087 0.81 FFAR1 (0.57) FFAR1DGAT1GSK3AGSK3BUCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737443-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Tanabe Pharma Corporation (JP) 2026-05-06 — — EP disclosed
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-03-05 — — US disclosed
WO-2025124429-A1 AROMATIC AMINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京康辰药业股份有限公司 2025-06-19 — — WO disclosed
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2025-03-06 — — US disclosed
EP-4050005-B1 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF CONVERGENE LLC (US) 2024-12-25 — — EP disclosed
WO-2024253416-A1 PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-12-12 — — WO disclosed
WO-2024242169-A1 SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 田辺三菱製薬株式会社 2024-11-28 — — WO disclosed
US-12110276-B2 Pyrazolo compounds and methods of use thereof GENENTECH, INC. (US) 2024-10-08 — — US disclosed
EP-4436957-A1 THERAPEUTIC INDAZOLE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-10-02 — — EP disclosed
WO-2024109660-A1 CDK INHIBITORS 上海齐鲁制药研究中心有限公司 2024-05-30 — — WO disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 — — US disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 — — US disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074881-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 FFAR1 4388/4885PDK2 838/4885CCNC 1116/4885
US-20260062387-A1 SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME SIK1, SIK3, SIK2 FFAR1 2539/4885PDK2 606/4885CCNC 2383/4885
US-20100063054-A1 cMET INHIBITORS CEPT1, LCAT, GNMT FFAR1 4031/4885PDK2 2264/4885CCNC 754/4885
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 FFAR1 4804/4885PDK2 188/4885CCNC 615/4885
US-12110276-B2 Pyrazolo compounds and methods of use thereof THPO, KLK3, TP53 FFAR1 4512/4885PDK2 23/4885CCNC 2493/4885
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A FFAR1 4610/4885PDK2 101/4885CCNC 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.